1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
3-D Matrix, Ltd.

3-D Matrix, Ltd.

7777.T
3-D Matrix, Ltd.JP flagTokyo Stock Exchange
380.00
JPY
+1.00
- -
45.68BMarket Cap
3-D Matrix, Ltd.
7777.T
(Tokyo Stock Exchange)

Recent

price

380.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
10.91
66.1
1.72
5.46
4.75
6.6
28.58
9.95
12.54
22.45
25.27
29.57
38.45
62.68
69.86
- -
41.5
Revenue per Share
-36.81
18.42
-52.63
-77.77
-94.89
-114.49
-64.62
-81.26
-97.41
-103.36
-49.65
-37.2
-40.64
-3.49
-25.2
- -
-2.91
Basic EPS, GAAP
-30.58
-13.17
-37.23
-87.67
-94.49
-70.1
-88.63
-89.2
-88.77
-73.7
-80.8
-57.26
-76.49
-26.01
-17.39
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-16.35
46.66
-6.82
-23.09
6.83
-107.21
-170.91
-208.68
-247.54
-292.39
-218.45
-186.75
-179.98
-135.85
-108.56
- -
- -
Book Value per Share
44.46
146.31
90.51
142.47
284.86
183.21
120.99
95.88
57.69
15.79
40.95
28.62
8.72
4.83
22.33
- -
- -
Tangible Book Value per Share
15
17
19
20
21
21
22
23
26
30
41
51
60
73
99
- -
91
Basic Weighted Avg Shares
158
1,107
32
107
100
142
616
229
329
672
1,024
1,506
2,314
4,589
6,934
- -
3,762
Sales/Revenue/Turnover
-304.73
31.98
-3,120.98
-1,416.95
-1,907.34
-1,284.22
-201.42
-819.99
-689.44
-377.2
-258.56
-181.69
-136.48
-46.13
-16.67
- -
-39.11
Operating Margin (%)
79
79
86
102
123
231
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-534
309
-978
-1,525
-1,995
-2,459
-1,393
-1,866
-2,555
-3,096
-2,013
-1,895
-2,446
-256
-2,501
- -
-264
Net Income, GAAP
- -
0.31
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
14.66
Effective Tax Rate (%)
-337.26
27.87
-3,056.04
-1,423.45
-1,999.44
-1,733.95
-226.12
-816.31
-776.82
-460.45
-196.47
-125.79
-105.7
-5.57
-36.07
- -
-7.02
Profit Margin (%)
618
2,389
1,571
2,634
5,795
3,898
2,572
2,177
2,787
1,847
2,702
4,710
4,365
4,255
4,840
- -
- -
Working Capital
- -
54
42
28
14
- -
- -
- -
1,300
1,400
1,050
3,265
3,874
3,874
2,641
- -
- -
LT Debt
1,150
2,888
2,066
3,133
6,382
3,936
2,607
2,202
1,513
473
1,660
1,458
525
353
2,216
- -
- -
Total Equity
- -
17.15
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
101.17
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.5
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jan'24
Apr'24
Jul'25
ST Debt
300
300
- -
LT Borrowings
3,874
3,874
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
82
- -
Market Capitalization
6,883
7,792
14,502

Working Capital

FRC

•

in mil. unless spec.
Jan'24
Apr'24
Jul'25
Total Current Assets
5,659
5,792
- -
Cash, Cash Equivalents & STI
1,274
1,364
- -
Accounts Receivable, Net
949
1,171
- -
Inventories
2,955
2,861
- -
Total Current Liabilities
1,160
1,537
- -
Payables & Accruals
- -
- -
- -
ST Debt
300
300
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
827
1,009
1,148
1,604
4,589
2025
- -
- -
- -
- -
6,934
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
- -
-3.49
2025
- -
- -
- -
- -
-25.2
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Nu-Med Plus, Inc. (NUMD)
Koninklijke Philips N.V. (RYLPF)
Longport, Inc. (LPTI)
Hemcheck Sweden AB (publ) (HEMC.ST)
Aplus Biotechnology Corporation Limited (6918.TWO)
Bluejay Diagnostics, Inc. (BJDX)
Business
3-D Matrix, Ltd. (7777.T) develops, manufactures, and sells self-assembling peptide-based medical products for surgery, regenerative medicine, and drug delivery systems; its core offerings include PuraStat, a synthetic hemostatic gel in prefilled syringes for managing bleeding in gastrointestinal endoscopic procedures and reducing delayed bleeds post-submucosal dissection; PuraBond, a transparent hemostatic gel for vascular anastomoses and parenchymal bleeding in solid organs; and PuraSinus for sinus applications, along with associated accessories for endoscopic and laparoscopic use. Founded in 2004 as an MIT spinoff and headquartered in Tokyo, Japan, the company operates globally through subsidiaries and offices in the United States, United Kingdom, Australia, Singapore, the Netherlands, and France, targeting healthcare providers, surgeons, and research institutions across Americas, Europe, Middle East, and Asia. Recent developments include FDA 510(k) clearance for PuraStat-GI in gastrointestinal endoscopy and Japanese National Health Insurance listing in 2021; formation of 3-D Matrix Medical Technology Pty Ltd in Australia for direct sales in 2019; and a private placement of series 9th unsecured convertible bonds raising ¥1.103 billion from CVI Investments, Inc. in June 2025 to support growth.